A standard chemotherapy regimen for HAIC has yet to be established, increasing the challenge of interpreting trial results.
HAIC的标准化疗方案尚未建立，这增加了解释试验结果的挑战。
Cisplatin and 5-FU were the most commonly used chemotherapeutic agents with various infusion protocols.
顺铂和5-FU是最常用的化疗药物，具有各种输注方案。
Other commonly used chemotherapeutic agents included oxaliplatin, carboplatin, epirubicin, and etoposide.
其他常用的化疗药物包括奥沙利铂、卡铂、表阿比星、依托泊苷。
The ORRs of these chemotherapies ranged from 5% to 71% in previous reports, with complete response rates of 1% to 5% [22,23,28,42,54].
在以前的报告中，这些化疗的orr在5%到71%之间，完全缓解率为1%至5%[22,23,28,42,54]。
Although no single regimen has been reported to demonstrate superiority over the others, differences may still exist among different regimens and various protocols.
虽然没有报道显示单一的方案优于其他方案，但在不同的方案和不同的方案之间可能仍然存在差异。
For example, doublet chemotherapy appeared to be associated with higher ORRs (30–40%) [26,44,46] compared with platinum alone (20–30%) [22,23,28,54]; moreover, regimens with higher doses (e.g., 5-FU at a total dose of >2000 mg/m2 or modified FOLFOX6) [23,42,47,48,49] probably engendered higher ORRs than did those with low doses of 5-FU (40–70% vs.30–40%) [22,28,38,54].
Investigators in China have reported encouraging results with consistent use of modified FOLFOX6 as an HAIC regimen, particularly when used in combination with PD-1/PD-L1 blockade [47,48,49,50].
Notably, two Phase 3 trials, ATTRACTION-4 [65] and CheckMate-649 trials [66], which both compared oxaliplatin-based chemotherapy with or without PD-1 blockade in advanced gastric cancer, showed longer OS in the combination arm.
值得注意的是，两项3期试验，ATTRACTION-4[65]和CheckeMate-649试验[66]，都比较了基于奥沙利铂的化疗与或没有PD-1阻断的进展期胃癌，在联合组显示了更长的OS。
The Keynote-062 trial [67], another Phase 3 trial, used cisplatin-based chemotherapy plus PD-1 blockade in the experimental arm and yielded similar OS compared with chemotherapy control arm.
基调-062试验[67]是另一项3期试验，在实验组中使用了顺铂基化疗加PD-1阻断，并产生了与化疗对照组相似的OS。
Whether oxaliplatin produces more synergistic effects with immunotherapy than cisplatin does remains unclear.
奥沙利铂是否在免疫治疗中比顺铂产生更多的协同作用尚不清楚。
Therefore, the potential distinct immune modulation effects of different chemotherapeutic agents warrant further investigation in HAIC.
因此，不同化疗药物对HAIC的潜在独特免疫调节作用值得进一步研究。
|